During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to “cut it off” or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is now above $60. In response, Jim Cramer said:
I think you take some profits. I mean, they’ve had, you know, look, they’ve had an exciting run. They do have stuff… It’s a biotech that’s been a winner, okay? I’d like to take a little bit off of the biotech winner and then let the rest run.
Record Revenue and Profitability Surge
Eton Pharmaceuticals, Inc.’s (NASDAQ:ETON) significant price appreciation is backed by impressive fundamental growth. The company delivered a blowout second quarter, reporting record product sales of $37.6 million, a staggering 99% increase year-over-year that easily topped consensus expectations by $10.5 million. The acceleration was fueled by the successful May relaunch of HEMANGEOL, which efficiently migrated existing patients onto its new direct specialty pharmacy distribution model, along with continued commercial expansion across its pediatric endocrinology portfolio, including DESMODA and INCRELEX.
Bottom-line metrics show this commercial momentum. Eton shifted from a net loss to reporting noteworthy GAAP net income, while adjusted earnings per share reached $0.43, comfortably beating Wall Street forecasts. Management also raised its full-year 2026 revenue guidance to exceed $145 million, supported by expanding operating leverage and a projected adjusted EBITDA margin of at least 35%.
Risks and the Bear Case Facing Eton
Despite the strong operational performance, several emerging headwinds could affect the stock. Eton Pharmaceuticals, Inc.’s (NASDAQ:ETON) adjusted gross margin experienced minor compression down to 73% in Q2, a contraction management attributed to higher international shipments of Increlex carrying negative gross margins, as mentioned in the company’s earnings press release. Execution risk remains bound to the company’s centralized distribution infrastructure, as the recent revenue surge depends on the seamless ongoing migration of patients to the proprietary Eton Cares single-pharmacy model.
Additionally, the stock’s parabolic climb (55.5% between August 13 and 18) to the $62–$63 range has triggered insider liquidation. Corporate executives and board members have aggressively trimmed their holdings, with CEO Sean Brynjelsen and Chief Business Officer David Krempa executing multi-million-dollar sales, according to data tracked by Insider Monkey. When top management extensively unloads shares during a massive rally, cautious institutional investors often view it as a signal that near-term upside is fully priced in.
Institutional Footprint
Smart money institutional interest in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is expanding. According to Insider Monkey’s Q2 data, the stock was held by 28 hedge funds, up from 20 in the prior quarter, which shows growing institutional conviction in the company’s rare-disease pipeline. Furthermore, short interest stands at a modest 4.82% of the public float.
Cramer’s advice is not a sign to give up on Eton, but a practical reminder to secure gains. After a massive run driven by its rare-disease products, taking some cash off the table while letting the remaining shares ride makes sense for long-term holders.
READ NEXT: Jim Cramer Advises Ditching Stellantis (STLA) for General Motors (GM) and Jim Cramer Discusses Restaurant Brands (QSR) Q2 Earnings and Burger King’s Resurgence.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center